guest ::
| Home > Publications database > Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. > print |
| Home > Publications database > Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. > print |
| 001 | 166506 | ||
| 005 | 20240229133522.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noaa276 |2 doi |
| 024 | 7 | _ | |a pmid:33331885 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:96266577 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-02949 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Adolph, Jonas E |b 0 |
| 245 | _ | _ | |a Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. |
| 260 | _ | _ | |a Oxford |c 2021 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1626177562_32275 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Jun 1;23(6):1012-1023 |
| 520 | _ | _ | |a Survival in recurrent ependymomas in children and adolescents mainly depends on the extent of resection. Studies on repeated radiotherapy and chemotherapy at relapse have shown conflicting results.Using data from the German multi-center E-HIT-REZ-2005 study, we examined the role of local therapy and the efficacy of chemotherapy with blockwise temozolomide (TMZ) in children and adolescents with recurrent ependymomas.53 patients with a median age of 6.9 years (1.25-25.4) at 1 st recurrence and a median follow-up time of 36 months (2-115) were recruited. Gross and near total resection (GTR/NTR) were achieved in 34 (64.2%) patients and associated with a markedly improved 5-year overall survival (OS) of 48.7% vs. 5.3% in less than GTR/NTR. Radiotherapy showed no improvement in OS following complete resection (OS: 70 (CI: 19.9-120.1) vs. 95 (CI: 20.7-169.4) months), but an advantage was found in less than GTR/NTR (OS: 22 (CI: 12.7-31.3) vs. 7 (CI: 0-15.8) months). Following application of TMZ, disease progression was observed in most evaluable cases (18/21). Subsequent change to oral etoposide and trofosfamide showed no improved response. PF-A EPN were most abundant in relapses (n = 27). RELA-positive EPN (n=5) had a 5-year-OS of 0%.The extent of resection is the most important predictor of survival at relapse. Focal re-irradiation is a useful approach if complete resection cannot be achieved, but no additional benefit was seen after GTR/NTR. Longer-term disease stabilization (>6 months) mediated by TMZ occurred in a small number of cases (14.3%). |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a chemotherapy |2 Other |
| 650 | _ | 7 | |a ependymoma |2 Other |
| 650 | _ | 7 | |a radiotherapy |2 Other |
| 650 | _ | 7 | |a relapse |2 Other |
| 650 | _ | 7 | |a tumor resection |2 Other |
| 700 | 1 | _ | |a Fleischhack, Gudrun |b 1 |
| 700 | 1 | _ | |a Mikasch, Ruth |b 2 |
| 700 | 1 | _ | |a Zeller, Julia |b 3 |
| 700 | 1 | _ | |a Warmuth-Metz, Monika |b 4 |
| 700 | 1 | _ | |a Bison, Brigitte |b 5 |
| 700 | 1 | _ | |a Mynarek, Martin |b 6 |
| 700 | 1 | _ | |a Rutkowski, Stefan |b 7 |
| 700 | 1 | _ | |a Schüller, Ulrich |b 8 |
| 700 | 1 | _ | |a von Hoff, Katja |b 9 |
| 700 | 1 | _ | |a Obrecht, Denise |b 10 |
| 700 | 1 | _ | |a Pietsch, Torsten |b 11 |
| 700 | 1 | _ | |a Pfister, Stefan M |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 12 |u dkfz |
| 700 | 1 | _ | |a Pajtler, Kristian W |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 13 |u dkfz |
| 700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 14 |u dkfz |
| 700 | 1 | _ | |a Witt, Hendrik |0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f |b 15 |u dkfz |
| 700 | 1 | _ | |a Kortmann, Rolf-Dieter |b 16 |
| 700 | 1 | _ | |a Timmermann, Beate |b 17 |
| 700 | 1 | _ | |a Krauß, Jürgen |b 18 |
| 700 | 1 | _ | |a Frühwald, Michael C |b 19 |
| 700 | 1 | _ | |a Faldum, Andreas |b 20 |
| 700 | 1 | _ | |a Kwiecien, Robert |b 21 |
| 700 | 1 | _ | |a Bode, Udo |b 22 |
| 700 | 1 | _ | |a Tippelt, Stephan |b 23 |
| 700 | 1 | _ | |a HIT-Network, German GPOH |b 24 |e Collaboration Author |
| 773 | _ | _ | |a 10.1093/neuonc/noaa276 |g p. noaa276 |0 PERI:(DE-600)2094060-9 |n 6 |p 1012-1023 |t Neuro-Oncology |v 23 |y 2021 |x 1523-5866 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:166506 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-08-32 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-08-32 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-08-32 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-08-32 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-08-32 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B310-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|